Difference between revisions of "Team:Queens Canada/Interviews"
| Line 17: | Line 17: | ||
<h3>Dr. Andrea Guerin <br>Department of Pediatrics, Queen’s University School of Medicine<h3> | <h3>Dr. Andrea Guerin <br>Department of Pediatrics, Queen’s University School of Medicine<h3> | ||
<img src="https://static.igem.org/mediawiki/2018/2/2f/T--Queens_Canada--Dr_Andrea_Guerin.jpeg/> | <img src="https://static.igem.org/mediawiki/2018/2/2f/T--Queens_Canada--Dr_Andrea_Guerin.jpeg/> | ||
| + | </div> | ||
<p>Dr. Andrea Guerin is a full time Assistant Professor in Pediatrics and Medical Geneticist. She is the Year 2 Director at Queen’s University Medical School. Her work in Medical Genetics includes a consultation practice consisting of general genetics, prenatal genetics, cancer genetics and the care of patients with inborn errors of metabolism. Interviewing Dr. Guerin was a great opportunity to hear her thoughts on the pros, cons, and potential applications of using cortisol as a useful biomarker, including revelations on hypoglycemia, insulinemia, and early diagnosis of developmental disabilities. In terms of the pacifier model, she suggested potential use of a saliva collection device, which would work well as a non-invasive method of collecting DNA from infants to do genetic testing. As well, Dr. Guerin found value in the modular design of our ligand detection system and offered the potential of looking at glucose and bilirubin as other relevant metabolites in the pediatric field.</p><br> | <p>Dr. Andrea Guerin is a full time Assistant Professor in Pediatrics and Medical Geneticist. She is the Year 2 Director at Queen’s University Medical School. Her work in Medical Genetics includes a consultation practice consisting of general genetics, prenatal genetics, cancer genetics and the care of patients with inborn errors of metabolism. Interviewing Dr. Guerin was a great opportunity to hear her thoughts on the pros, cons, and potential applications of using cortisol as a useful biomarker, including revelations on hypoglycemia, insulinemia, and early diagnosis of developmental disabilities. In terms of the pacifier model, she suggested potential use of a saliva collection device, which would work well as a non-invasive method of collecting DNA from infants to do genetic testing. As well, Dr. Guerin found value in the modular design of our ligand detection system and offered the potential of looking at glucose and bilirubin as other relevant metabolites in the pediatric field.</p><br> | ||
Revision as of 18:32, 28 July 2018
Expert Interviews
Dr. Andrea Guerin
Department of Pediatrics, Queen’s University School of Medicine
 Steering Committees and is a member of the Board of Directors for the Canadian Pediatric Society. During our interview with Dr. Dow, we were able to gain valuable knowledge about daily procedures and processes that take place in Neonatal Intensive Care Units (NICU). By evaluating current practices involved in the maintenance of neonate well-being and pain-mitigation during different procedures, we were able to better understand how our project design could be implemented and beneficial in this setting. One of the specific applications that were elaborated on during our time with Dr. Dow was the use of our technology to aid in Newborn Abstinence Syndrome treatment plans and morphine dosage determination. The other application we discussed was the possibility of aiding with the use of sucrose as an analgesic for neonates, and determining the efficacy of this pain-reducing method that is currently employed. By creating a device that can quantify cortisol, stress and pain affecting non-verbal individuals can be better understood and managed to prevent detrimental developmental effects.</p><br>
<h3>Dr. Harriet Feilotter <br>Department of Pathology and Molecular Medicine, Queen’s University</h3>
<!-- IMAGE IN HERE -->
<p>Dr. Harriet Feilotter is an Associate Professor in the Department of Pathology and Molecular Medicine at Queen’s University. Her research focuses on the development of biomarkers to be used in the screening, diagnosis and treatment of human diseases in clinical settings. Our meeting with Dr. Feilotter was very informative and provided a lot of insight into what research is required to validate our biosensor technology and demonstrate its effectiveness and clinical utility. She provided information pertaining to important parameters that must be evaluated when working with biomarkers, including analytic and clinical specificity and sensitivity values, negative and positive predictive values, the concentration range our technology can measure, the saturation point of our assay and cross-reactivity that might occur with molecules resembling cortisol. Dr. Feilotter was also very knowledgeable about the safety testing and potential experiments that may be useful in demonstrating the validity and safety of our device.</p><br>
</div>
</body>
</p>
<!--
NewPP limit report
CPU time usage: 0.005 seconds
Real time usage: 0.013 seconds
Preprocessor visited node count: 16/1000000
Preprocessor generated node count: 75/1000000
Post‐expand include size: 124/2097152 bytes
Template argument size: 0/2097152 bytes
Highest expansion depth: 3/40
Expensive parser function count: 0/100
-->
</div> <div class=)